| Boosting natural killer cell-mediated targeting of sarcoma through DNAM-1 and NKG2D EC Sayitoglu, AM Georgoudaki, M Chrobok, D Ozkazanc, BJ Josey, M Arif, ... Frontiers in immunology 11, 40, 2020 | 48 | 2020 |
| Successive crystal structure snapshots suggest the basis for MHC class I peptide loading and editing by tapasin I Hafstrand, EC Sayitoglu, A Apavaloaei, BJ Josey, R Sun, X Han, ... Proceedings of the National Academy of Sciences 116 (11), 5055-5060, 2019 | 44 | 2019 |
| Engineering antigen‐specific NK cell lines against the melanoma‐associated antigen tyrosinase via TCR gene transfer A Parlar, EC Sayitoglu, D Ozkazanc, AM Georgoudaki, C Pamukcu, ... European journal of immunology 49 (8), 1278-1290, 2019 | 38 | 2019 |
| Functional assessment for clinical use of serum-free adapted NK-92 cells M Chrobok, CIM Dahlberg, EC Sayitoglu, V Beljanski, H Nahi, M Gilljam, ... Cancers 11 (1), 69, 2019 | 23 | 2019 |
| The Yin and Yang of type 1 regulatory T cells: from discovery to clinical application EC Sayitoglu, RA Freeborn, MG Roncarolo Frontiers in Immunology 12, 693105, 2021 | 22 | 2021 |
| Engineered type 1 regulatory T cells designed for clinical use kill primary pediatric acute myeloid leukemia cells B Cieniewicz, MJ Uyeda, PP Chen, EC Sayitoglu, JMH Liu, G Andolfi, ... haematologica 106 (10), 2588, 2021 | 14 | 2021 |
| Characterization of zika virus infection of human fetal cardiac mesenchymal stromal cells F Rossi, B Josey, EC Sayitoglu, R Potens, T Sultu, AD Duru, V Beljanski PloS one 15 (9), e0239238, 2020 | 13 | 2020 |
| Pre-clinical development and molecular characterization of an engineered type 1 regulatory T-cell product suitable for immunotherapy JMH Liu, P Chen, MJ Uyeda, B Cieniewicz, EC Sayitoglu, BC Thomas, ... Cytotherapy 23 (11), 1017-1028, 2021 | 6 | 2021 |
| Abstract A55: Natural killer cells genetically modified to overexpress DNAM-1 exert enhanced antitumor responses against CD112/CD155+ sarcomas and other malignancies EC Sayitoglu, M Chrobok, AM Georgoudaki, BJ Josey, M Hartman, ... Cancer Immunology Research 8 (4 Supplement), A55-A55, 2020 | 1 | 2020 |
| AML/T cell interactomics uncover correlates of patient outcomes and the key role of ICAM1 in T cell killing of AML EC Sayitoglu, BA Luca, AP Boss, BC Thomas, RA Freeborn, MJ Uyeda, ... bioRxiv, 2023.09. 21.558911, 2023 | | 2023 |
| Unraveling Transcriptomic Profiles of Pediatric Acute Myeloid Leukemia Cells Sensitive or Resistant to Cytotoxic Killing by Engineered TR1-like Cells EC Sayitoglu, B Luca, B Thomas, B Cieniewicz, M Uyeda, P Chen, ... MOLECULAR THERAPY 30 (4), 153-153, 2022 | | 2022 |
| Characterization of zika virus infection of human fetal cardiac mesenchymal stromal cells (vol 15, e0239238, 2020) F Rossi, B Josey, EC Sayitoglu, R Potens, T Sutlu, AD Duru, V Beljanski PLOS ONE 16 (1), 2021 | | 2021 |
| Correction: Characterization of zika virus infection of human fetal cardiac mesenchymal stromal cells F Rossi, B Josey, EC Sayitoglu, R Potens, T Sutlu, AD Duru, V Beljanski Plos one 16 (1), e0246112, 2021 | | 2021 |
| Engineering antigen-specific natural killer cells against the melanoma-associated antigen tyrosinase via TCR gene transfer. A Parlar, EC Sayitoglu, C Pamukcu, AM Georgoudaki, D Ozkazanc, ... CANCER IMMUNOLOGY RESEARCH 8 (4), 49-50, 2020 | | 2020 |
| Abstract A21: Engineering antigen-specific natural killer cells against the melanoma-associated antigen tyrosinase via TCR gene transfer A Parlar, EC Sayitoglu, C Pamukcu, AM Georgoudaki, D Ozkazanc, ... Cancer Immunology Research 8 (4 Supplement), A21-A21, 2020 | | 2020 |
| Natural killer cells genetically modified to overexpress DNAM-1 exert enhanced antitumor responses against CD112/CD155+ sarcomas and other malignancies. EC Sayitoglu, M Chrobok, AM Georgoudaki, BJ Josey, M Hartman, ... CANCER IMMUNOLOGY RESEARCH 8 (4), 64-65, 2020 | | 2020 |
| Identification and strategic targeting of key anti-viral defense mechanisms in Natural Killer cells EC Sayitoglu, D Ozkazanc, A Sarac, A Parlar, E Alici, B Erman, AD Duru, ... The Journal of Immunology 200 (1 Supplement), 169.19-169.19, 2018 | | 2018 |
